Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:3948 |
Name | adrenocortical carcinoma |
Definition | An adrenal cortex cancer that forms in the outer layer of tissue of the adrenal gland and that has_material_basis_in abnormally proliferating cells derives_from epithelial cells. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer endocrine gland cancer adrenal gland cancer adrenal cortex cancer adrenocortical carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
FGFR1 amp | Derazantinib | adrenocortical carcinoma | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01898715 | Phase I | ATR-101 | Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma | Completed | USA | DEU | 0 |
NCT02720484 | Phase II | Nivolumab | Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer | Terminated | USA | 0 |
NCT02721732 | Phase II | Pembrolizumab | Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors | Active, not recruiting | USA | 0 |
NCT03333616 | Phase II | Ipilimumab + Nivolumab | Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors | Active, not recruiting | USA | 0 |
NCT03370718 | Phase II | Cabozantinib | Cabozantinib in Unresectable/Metastatic Adrenocortical Carcinoma | Completed | USA | 0 |
NCT03612232 | Phase II | Cabozantinib | Cabozantinib in Advanced Adrenocortical Carcinoma (CaboACC) | Active, not recruiting | DEU | 0 |
NCT04187404 | Phase Ib/II | EO2401 + Nivolumab | A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma (Spencer) | Terminated | USA | SWE | NLD | ITA | FRA | ESP | DNK | DEU | 0 |
NCT04373265 | Phase I | Pembrolizumab + Relacorilant | Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma With Excess Glucocorticoid Production | Completed | USA | 0 |
NCT04400474 | Phase II | Atezolizumab + Cabozantinib | Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study (CABATEN) | Active, not recruiting | ESP | 0 |
NCT04544995 | Phase I | Dostarlimab-gxly + Niraparib | Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Pediatric Participants With Solid Tumors | Recruiting | HUN | GBR | FRA | ESP | DEU | CZE | 0 |
NCT05563467 | Phase II | Pembrolizumab | Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma. (PEMBR-01) | Recruiting | POL | 0 |
NCT05634577 | Phase II | Mitotane + Pembrolizumab | A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma | Completed | USA | 0 |
NCT05841563 | Phase I | PM54 | Clinical Trial of PM54 in Advanced Solid Tumors Patients. | Recruiting | USA | ESP | BEL | 0 |
NCT06006013 | Phase II | Atezolizumab + Cabozantinib | Cabozantinib in Combination With Atezolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer | Active, not recruiting | USA | 0 |
NCT06041516 | Phase I | ADCT-701 | Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas | Recruiting | USA | 0 |
NCT06066333 | Phase II | Pembrolizumab | Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma | Recruiting | USA | 0 |
NCT06333314 | Phase II | Dostarlimab-gxly Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Doxorubicin Gemcitabine Gemcitabine + Nab-paclitaxel Doxorubicin + Trabectedin Fluorouracil + Leucovorin + Oxaliplatin Cisplatin + Etoposide Cisplatin + Gemcitabine Cisplatin + Doxorubicin + Etoposide Capecitabine + Oxaliplatin Doxorubicin + Ifosfamide Carboplatin + Etoposide Carboplatin + Paclitaxel Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin Mitotane | Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI (Pan-MSI-ACSE) | Recruiting | FRA | 0 |